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Introduction 
In tissue engineering (TE), the ideal cell source to be used 
in a wide spectrum of applications is yet to be found. 
Bone marrow mesenchymal stem cells (BMSCs) have 
been widely studied, indicating that BMSCs can be 
differentiated into cells of the osteogenic lineage. Thus, 
BMSCs have become the gold standard for studies in 
orthopaedic TE. However, novel stem cell sources, such 
as amniotic fluid stem cells (AFSCs) have been identified, 
showing important and unique features that may allow 
successful applications in the regeneration of bone tissue.  
This study was designed to compare the osteogenic 
potential of both BMSCs and AFSCS under distinct 
culture environments in order to determine whether the 
osteogenic differentiation process of both types of stem 
cells is related to the origin of the cells.  Osteogenic 
differentiation was carried out in two and three 
dimensions (3D) using a culture treated plate and by 
seeding the cells onto microfibrous SPCL scaffolds (a 
blend of starch and poly-caprolactone), respectively.  
 
Materials and Methods 
Human BMSCs, purchased from Lonza®, were expanded 
in basal BMSCs medium: α-MEM, 10% embryonic 
screened-FBS (ES-FBS, HyClone) and 1% penicillin 
/streptavidin solution. hAFSCs were isolated as described 
previously
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, and cultured in basic hAFCs medium 
(BAFC) composed of α-MEM (HyClone), 18% Chang B 
(Irvine Scientific), 1% Chang C (Irvine Scientific) media, 
2% L-glutamine (HyClone) and 15% ES-FBS. 
hBMSCs and hAFSCs were seeded onto tissue culture 
plates (2D culture) at passage 5 and 24, respectively, with 
30,000 cells/well. Cells were cultured for 3 days in basal 
medium, and then exchanged to osteogenic medium, 
composed of DMEM with 10% FBS (HyClone), 100 nM 
dexamethasone (Sigma), 50 µM L-ascorbic acid (Sigma) 
and 10 mM glycerol 2-phosphate disodium salt hydrate 
(Sigma) for up to 3 weeks (0, 7, 14 and 21 days). To study 
the behavior of hBMSCs and hAFSCs in a 3D milieu, 
both type of cells were seeded onto SPCL scaffolds (7 
mm x 4 mm cylinders) produced by fiber bonding
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 at a 
concentration of 1.2x10
6 
cells/scaffold. Similarly to 2D 
culture, cells were cultured in basal medium for 3 days 
and then in osteogenic media for up to 3 weeks. 
Retrieved samples were characterized for cellular viability 
with Calcein AM and for the presence of osteogenic 
markers and matrix formation by alkaline phosphatase 
(ALP) and Alizarin Red (AR) stainings as well as the 
presence of runx-2 and collagen I in the matrix by 
immunofluorescence. Cell morphology and matrix 
formation in the 3D environment, were also assessed by 
scanning electronic microscopy (SEM).  
 
Results and Discussion 
AFSCs and BMSCs proliferated and colonized in both 2D 
and 3D substrates, and for both cells, it was detected the 
presence of osteogenic markers and mineralized matrix 
formation. Nevertheless, AFSCs showed higher 
proliferation rate and enhanced mineralization of the 
ECM in 2D cultures, when compared to BMSCs. 
In a 3D environment, ECM mineralization was observed 
at 14 and 21 days for BMSCs and AFSCs, respectively, 
and changes in the expression of bone related markers 
from 2D to 3D cultures were cell origin related, indicating 
that culture environments also play an important role in 
cellular response during osteogenic differentiation. 
Furthermore, the collagen fibers covering the scaffolds 
seem to be aligned, showing some degree of organization. 
Despite similar viability and RunX2 levels during the 
experimental study, as well as collagen I levels after 21 
days in osteo culture, BMSCs and AFSCs showed a 
different behavior in terms of mineralization; not only 
mineralization occurs latter in AFSCs constructs but 
BMSCs also produced more mineralized matrix, when 
seeded onto SPCL scaffolds. The continuous expression 
of RunX-2 of BMSCs in SPCL scaffolds also indicates 
that osteoblast differentiation process is likely to continue 
in time, reinforcing the ECM production and maturation.  
 
Conclusions  
BMSCs and AFSCs were successfully differentiated into 
the osteogenic lineage with production of mineralized 
ECM. However the two cell types presented different 
expression patterns of bone-related markers, and different 
timings of differentiation, indicating that both cell origin 
and the culture environment have a significant impact on 
the differentiation of stem cells into the osteogenic 
phenotype. 
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